Monday, 26 October 20265:09 pm ISTIndia edition

सच, सीधे आप तक

Book ad space

Just in

Business

Phase 3 Trial Finds Longer Median Survival With Divarasib

Image: Econotimes. Rights remain with the publisher.

Median overall survival was 17.7 months with divarasib and 12.0 months with sotorasib or adagrasib in patients with previously treated KRAS G12C-mutated lung cancer.

Read the full report on Econotimes

Story file

Section
Business
Topics
Health alerts
First reported by
Econotimes
Reporter
naomi calder
Published
Monday, 26 October 2026, 2:21 am IST
Coverage
One outlet so far

How this page works. The Headline Update lists this report from Econotimes with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.

Related stories

More Business news

See all